Vermunt Jane V, Kennedy Stephen H, Garovic Vesna D
Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, UK.
Division of Nephrology and Hypertension, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA.
Curr Hypertens Rep. 2020 Feb 1;22(1):10. doi: 10.1007/s11906-019-1014-z.
This review discusses the mortality and morbidity of hypertensive disorders of pregnancy (HDP) and the current diagnostic thresholds. It then explores measurement of variability in blood pressure (BP) during pregnancy as an opportunity to identify women at high risk of cardiovascular disease (CVD) later in life.
HDP is known to be associated with increased risk of long-term CVD. Current CVD prognostic tools do not incorporate a history of HDP given a lack of improved risk discrimination. However, HDP diagnostic criteria are currently based on a binary threshold, and there is some evidence for the use of variability in BP throughout gestation as a marker of CVD risk. HDP increases long-term risk of CVD. Future studies investigating changes in diagnostic criteria, including the use of BP variability, may improve long-term CVD risk prediction and be incorporated into future risk assessment tools.
本综述讨论了妊娠高血压疾病(HDP)的死亡率和发病率以及当前的诊断阈值。然后探讨了孕期血压(BP)变异性的测量,以此作为识别日后有心血管疾病(CVD)高风险女性的契机。
已知HDP与长期CVD风险增加有关。鉴于缺乏改善的风险辨别能力,当前的CVD预后工具未纳入HDP病史。然而,HDP诊断标准目前基于二元阈值,并且有一些证据表明,将整个孕期的BP变异性用作CVD风险的标志物。HDP会增加CVD的长期风险。未来研究诊断标准的变化,包括使用BP变异性,可能会改善CVD长期风险预测,并纳入未来的风险评估工具中。